Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001415889-25-021493·Compass Therapeutics, Inc.
Schedule 13G ownership disclosure
Compass Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 20454B104
Event date: 2025-06-30
- Filing-level shares
- 5,622,505.00
- Percent of class
- 4.1%
- MPM BioImpact LLC
Shares: 5,622,505.00 · Class: 4.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-021493
- Form type
- SCHEDULE 13G/A
- Filer
- Compass Therapeutics, Inc.
- CIK
- CIK 1738021
- Filed
- Aug 12, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership